These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

162 related items for PubMed ID: 16193557

  • 1. New light on statin side effects. What recent research on the cholesterol drugs means to you.
    Heart Advis; 2005 Aug; 8(8):3. PubMed ID: 16193557
    [No Abstract] [Full Text] [Related]

  • 2. Paradoxical decrease in HDL-cholesterol and apolipoprotein A1 with simvastatin and atorvastatin in a patient with type 2 diabetes.
    Ramachandran S, Saraf S, Shetty C, Capps N, Bailey C.
    Ann Clin Biochem; 2011 Jan; 48(Pt 1):75-8. PubMed ID: 21115572
    [Abstract] [Full Text] [Related]

  • 3. A survey of the FDA's AERS database regarding muscle and tendon adverse events linked to the statin drug class.
    Hoffman KB, Kraus C, Dimbil M, Golomb BA.
    PLoS One; 2012 Jan; 7(8):e42866. PubMed ID: 22936996
    [Abstract] [Full Text] [Related]

  • 4. [Statin therapy and muscle disorders].
    Abel T, Fehér J.
    Orv Hetil; 2009 Feb 08; 150(6):261-3. PubMed ID: 19179258
    [No Abstract] [Full Text] [Related]

  • 5. [Randomized head-to-head comparison of pitavastatin, atorvastatin, and rosuvastatin for safety and efficacy (quantity and quality of LDL): -- the PATROL trial].
    Saku K, Zhang B, Noda K.
    Nihon Naika Gakkai Zasshi; 2011 Dec 10; 100(12):3679-86. PubMed ID: 22338904
    [No Abstract] [Full Text] [Related]

  • 6. Recurrent acute pancreatitis possibly induced by atorvastatin and rosuvastatin. Is statin induced pancreatitis a class effect?
    Singh S, Nautiyal A, Dolan JG.
    JOP; 2004 Nov 10; 5(6):502-4. PubMed ID: 15536291
    [Abstract] [Full Text] [Related]

  • 7. Risk of incident diabetes among patients treated with statins: population based study.
    Carter AA, Gomes T, Camacho X, Juurlink DN, Shah BR, Mamdani MM.
    BMJ; 2013 May 23; 346():f2610. PubMed ID: 23704171
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and safety of fenofibric acid co-administered with low- or moderate-dose statin in patients with mixed dyslipidemia and type 2 diabetes mellitus: results of a pooled subgroup analysis from three randomized, controlled, double-blind trials.
    Jones PH, Cusi K, Davidson MH, Kelly MT, Setze CM, Thakker K, Sleep DJ, Stolzenbach JC.
    Am J Cardiovasc Drugs; 2010 May 23; 10(2):73-84. PubMed ID: 20136164
    [Abstract] [Full Text] [Related]

  • 9. N-of-1 (single-patient) trials for statin-related myalgia.
    Joy TR, Zou GY, Mahon JL.
    Ann Intern Med; 2014 Oct 07; 161(7):531-2. PubMed ID: 25285548
    [No Abstract] [Full Text] [Related]

  • 10. N-of-1 (single-patient) trials for statin-related myalgia.
    Akinboro O, Williams L, Pomerantz D.
    Ann Intern Med; 2014 Oct 07; 161(7):531. PubMed ID: 25285547
    [No Abstract] [Full Text] [Related]

  • 11. Discontinuation of statin therapy due to muscular side effects: a survey in real life.
    Rosenbaum D, Dallongeville J, Sabouret P, Bruckert E.
    Nutr Metab Cardiovasc Dis; 2013 Sep 07; 23(9):871-5. PubMed ID: 22748604
    [Abstract] [Full Text] [Related]

  • 12. Strong statins as the major players for dyslipidemia in high-risk patients: are they all the same or not?
    Ikewaki K, Ayaori M.
    Circ J; 2011 Sep 07; 75(6):1326-7. PubMed ID: 21532174
    [No Abstract] [Full Text] [Related]

  • 13. Achieving LDL cholesterol, non-HDL cholesterol, and apolipoprotein B target levels in high-risk patients: Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapY (MERCURY) II.
    Ballantyne CM, Bertolami M, Hernandez Garcia HR, Nul D, Stein EA, Theroux P, Weiss R, Cain VA, Raichlen JS.
    Am Heart J; 2006 May 07; 151(5):975.e1-9. PubMed ID: 16644314
    [Abstract] [Full Text] [Related]

  • 14. How safe is aggressive statin therapy?
    Guthrie RM.
    Prog Cardiovasc Nurs; 2006 May 07; 21(3):140-5. PubMed ID: 16957460
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Incremental cholesterol reduction with ezetimibe/simvastatin, atorvastatin and rosuvastatin in UK General Practice (IN-PRACTICE): randomised controlled trial of achievement of Joint British Societies (JBS-2) cholesterol targets.
    McCormack T, Harvey P, Gaunt R, Allgar V, Chipperfield R, Robinson P, IN-PRACTICE study.
    Int J Clin Pract; 2010 Jul 07; 64(8):1052-61. PubMed ID: 20487050
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Summaries for patients. Treatment trials to determine whether statins are the cause of a patient's discomfort.
    Ann Intern Med; 2014 Mar 04; 160(5):I-34. PubMed ID: 24737270
    [No Abstract] [Full Text] [Related]

  • 19. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study.
    Strandberg TE, Feely J, Sigurdsson EL, DISCOVERY study group.
    Clin Ther; 2004 Nov 04; 26(11):1821-33. PubMed ID: 15639694
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.